1. Home
  2. TKNO vs VCRE Comparison

TKNO vs VCRE Comparison

Compare TKNO & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$9.33

Market Cap

268.1M

Sector

Health Care

ML Signal

HOLD

Logo Vicore Pharma Holding AB American Depositary Shares

VCRE

Vicore Pharma Holding AB American Depositary Shares

N/A

Current Price

$9.55

Market Cap

316.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TKNO
VCRE
Founded
1996
N/A
Country
United States
Sweden
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
268.1M
316.4M
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
TKNO
VCRE
Price
$9.33
$9.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 201.7K
16.6K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 43.86
N/A
EPS
N/A
★ N/A
Revenue
★ $40,520,000.00
N/A
Revenue This Year
$8.27
N/A
Revenue Next Year
$13.13
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 7.35
N/A
52 Week Low
$1.91
$9.50
52 Week High
$9.41
$13.15

Technical Indicators

Market Signals
Indicator
TKNO
VCRE
Relative Strength Index (RSI) 73.40 N/A
Support Level $4.87 N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.47 0.00
MACD 0.17 0.00
Stochastic Oscillator 80.13 0.00

Price Performance

Historical Comparison
TKNO
VCRE

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

About VCRE Vicore Pharma Holding AB American Depositary Shares

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Share on Social Networks: